Many branches of the industry are joining the hype around using deep neural networks or complex machine learning approaches, eg gradient boosting machines, random forests. However, I am sceptical that these “black box” algorithms will make major contributions to  drug development, since the problems in clinical trials seems conceptually different from, eg image or speech … Continue reading Limitations of use of machine learning/deep learning in drug development